RELAY THERAPEUTICS, INC.

(RLAY)
  Bericht
Verzögert Nasdaq  -  22:00 18.08.2022
19.64 USD   +1.55%
09.08.RELAY THERAPEUTICS, INC. : HC Wainwright bleibt bei seiner Kaufempfehlung
MM
05.08.RELAY THERAPEUTICS, INC. : Goldman Sachs behält die Bewertung Kaufen bei
MM
04.08.Relay Therapeutics, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2022
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über RELAY THERAPEUTICS, INC.
18.08.Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
18.08.Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
08.08.INSIDER SELL : Relay Therapeutics
04.08.RELAY THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Corporate Highlight..
04.08.RELAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
04.08.Relay Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months..
04.08.Earnings Flash (RLAY) RELAY THERAPEUTICS Posts Q2 Revenue $365,000
04.08.RELAY THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
04.08.Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highligh..
04.08.Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highligh..
28.07.Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate High..
27.07.RELAY THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
27.07.Relay Therapeutics, Inc. Announces Appointment of Sekar Kathiresan to the Board
08.07.INSIDER SELL : Relay Therapeutics
27.06.RELAY THERAPEUTICS : June 2022 Corporate Presentation
27.06.RELAY THERAPEUTICS : Discloses Anticipated Registrational Path for RLY-4008 in Cholangioca..
27.06.RELAY THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements an..
27.06.Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangioc..
27.06.Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangioc..
16.06.Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
16.06.Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
27.05.RELAY THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
26.05.Relay Therapeutics to Participate in Two Upcoming Investor Conferences
26.05.Relay Therapeutics to Participate in Two Upcoming Investor Conferences
05.05.Earnings Flash (RLAY) RELAY THERAPEUTICS Posts Q1 Revenue $419,000
05.05.Earnings Flash (RLAY) RELAY THERAPEUTICS Posts Q1 Loss $-0.57, vs. Street Est of $-0.62
05.05.RELAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
05.05.RELAY THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
05.05.Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
05.05.Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlight..
05.05.Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlight..
03.05.INSIDER SELL : Relay Therapeutics
03.05.Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 H..
28.04.Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highl..
28.04.Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highl..
18.04.INSIDER SELL : Relay Therapeutics
05.04.INSIDER SELL : Relay Therapeutics
03.03.INSIDER SELL : Relay Therapeutics
24.02.RELAY THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Corpo..
24.02.Earnings Flash (RLAY) RELAY THERAPEUTICS Posts Q4 Revenue $3.03M
24.02.RELAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
24.02.RELAY THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
24.02.Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, ..
24.02.Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corp..
17.02.Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and ..
17.02.Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and ..
02.02.Relay Therapeutics to Participate in Two Upcoming Investor Conferences
21.01.BB Biotech boucle l'année 2021 sur une perte
11.01.Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement End..
11.01.Certain Options of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending o..
11.01.Certain Restricted Stock Units of Relay Therapeutics, Inc. are subject to a Lock-Up Agr..
10.01.RELAY THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
04.01.Relay Therapeutics Doses First Patient in First-in-Human Cancer Drug Trial
04.01.Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-260..
04.01.Relay Therapeutics, Inc. Announces Dosing of First Patient in First-in-Human Trial of R..
03.01.Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
2021Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-..
2021Relay Therapeutics, Inc. Announces Preclinical Data that Support Clinical Development o..
2021RELAY THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
2021Relay Therapeutics, Inc. Announces Resignation of Dipchand Nishar as Class III Director..
2021RELAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
2021Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Hi..
2021Relay Therapeutics Posts Narrower Q3 Loss, Sees Sufficient Funding Into 2025
2021Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
2021RELAY THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
2021Earnings Flash (RLAY) RELAY THERAPEUTICS Posts Q3 Loss $-0.66, vs. Street Est of $-0.64
2021Earnings Flash (RLAY) RELAY THERAPEUTICS Posts Q3 Revenue $666,000, vs. Street Est of $..
2021Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Hi..
2021Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporat..
2021INSIDER SELL : Relay Therapeutics
2021RELAY THERAPEUTICS : Announces Proposed Public Offering of Common Stock - Form 8-K
2021RELAY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operatio..
2021RELAY THERAPEUTICS : Shares Gain in Afternoon Trading
2021Health Care Stocks Edging Higher Ahead of Wednesday Close
2021Health Care Stocks Finding Increased Support This Afternoon
1  2  3Weiter
Anstehende Termine für RELAY THERAPEUTICS, INC.